Updates on Pharmacologic Management of Microvascular Angina

Table 1

Recently-published articles on management of MVA.

Study	Design	Treatment	Duration	Results	Ref
Henry et al. [206]	Pilot clinical trial	Autologous CD34+ stem cell therapy	180 days	(i) Improved coronary flow reserve ( changed to ; ); (ii) Decreased angina frequency (); (iii) Improved Canadian cardiovascular society class (); (iv) Improved quality of life ()	[206]
Zhang et al. [55]	RCT	Group 1: fluvastatin (statin; 40 mg daily); Group 2: diltiazem (CCB; 90 mg daily); Group 3: statin and CCB	90 days	(i) Improved coronary flow reserve (23.2%, 12.4%, and 29.1% in groups 1 to 3, respectively; ); (ii) Increased time to 1 mm ST segment depression ( to , in group 1; to , in group 2, and to , in group 3)	[55]
Kabaklić et al. [207]	Pilot RCT	Atorvastatin (20 mg daily)	90 and 180 days	(i) Improved flow-mediated dilation ( for 90 and 180 days); (ii) No difference in reactive hyperemia index; (iii) Insignificant improvement in rate-normalized augmentation index ()	[207]
Makarewicz-Wujec et al. [208]	RCT	DASH diet	12 months	(i) Insignificant reduction in RANTES ( to , ); (ii) Reduced CXCL4 ( to , )	[208]

Ref: reference; RCT: randomized controlled trial; CCB: calcium channel blocker; DASH: dietary approaches to stop hypertension.